ESRP1通过ER调节的转录程序和EMT相关的拼接开关驱动特定亚型的乳腺癌进展
Xinyi Wang1,2, Shuping Song2, Weixuan Lin3
1Cancer Center, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University Dongguan, Guangdong, The People's Republic of China.
American journal of cancer research
|July 16, 2025
概括
表皮剪接调节蛋白1 (ESRP1) 在乳腺癌中升高,影响患者的治疗结果. 它的作用因雌激素受体状态而异,表明亚型特定的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 表皮拼接调节蛋白1 (ESRP1) 是一种表皮拼接调节剂.
- 已知ESRP1在乳腺癌侵入性和转移中的作用,但其预后价值和与雌激素受体 (ER) 的相互作用需要进一步阐明.
研究的目的:
- 为了研究ESRP1在乳腺癌的预后意义.
- 探索ESRP1和雌激素受体 (ER) 在乳腺癌进展中的功能相互作用.
主要方法:
- 对乳腺癌组织中ESRP1表达的分析.
- 使用ER阳性和ER阴性乳腺癌细胞系的体外研究.
- 对ESRP1表达和ER信号通路的操纵.
主要成果:
- 乳腺癌中ESRP1上调,并与不良结果相关,特别是在ER阳性病例中.
- 抑制ESRP1抑制了ER阳性细胞的增殖,但影响了ER阴性细胞的入侵/迁移.
- 在ER阳性细胞中,ESRP1抑制促进EMT并增强入侵,表明依赖于ER状态的复杂调控作用.
结论:
- ESRP1是乳腺癌的潜在预后标志物,其意义是亚型特定的.
- 由于ESRP1的治疗向需要仔细考虑ER的背景,因为其取决于环境的功能.
相关概念视频
Master Transcription Regulators
7.1K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.1K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
Regulation of the Unfolded Protein Response
2.6K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.6K
Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
RNA Splicing
57.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.1K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


